447 filings
Page 11 of 23
6-K
BFFTF
Biofrontera AG
4 Mar 20
Current report (foreign)
10:32am
6-K
BFFTF
Biofrontera AG
2 Mar 20
Announcement of a subscription rights offering for the 0.5% qualified subordinated mandatory convertible bond 2020/2024
6:05am
FWP
BFFTF
Biofrontera AG
27 Feb 20
Free writing prospectus
9:42pm
424B3
BFFTF
Biofrontera AG
26 Feb 20
Prospectus supplement
5:05pm
6-K
BFFTF
Biofrontera AG
26 Feb 20
Current report (foreign)
8:48am
6-K
BFFTF
Biofrontera AG
19 Feb 20
Biofrontera provides clinical development updates
7:56am
EFFECT
BFFTF
Biofrontera AG
19 Feb 20
Notice of effectiveness
12:15am
424B3
BFFTF
Biofrontera AG
18 Feb 20
Prospectus supplement
4:59pm
CORRESP
BFFTF
Biofrontera AG
13 Feb 20
Correspondence with SEC
12:00am
CORRESP
BFFTF
Biofrontera AG
13 Feb 20
Correspondence with SEC
12:00am
F-3/A
BFFTF
Biofrontera AG
12 Feb 20
Shelf registration (foreign) (amended)
5:31pm
6-K
BFFTF
Biofrontera AG
12 Feb 20
Current report (foreign)
4:46pm
SC 13D/A
Deutsche Balaton Aktiengesellschaft
3 Feb 20
Biofrontera AG
5:14pm
6-K
BFFTF
Biofrontera AG
3 Feb 20
Current report (foreign)
2:59pm
6-K
BFFTF
Biofrontera AG
3 Feb 20
European Medicines Agency recommends indication expansion of AmeluzĀ® for treatment of actinic keratoses on the extremities and trunk/neck
6:41am
6-K
BFFTF
Biofrontera AG
31 Jan 20
Current report (foreign)
1:18pm
UPLOAD
BFFTF
Biofrontera AG
28 Jan 20
Letter from SEC
12:00am
F-3
BFFTF
Biofrontera AG
22 Jan 20
Shelf registration (foreign)
5:28pm
6-K
BFFTF
Biofrontera AG
22 Jan 20
Current report (foreign)
5:20pm
6-K
BFFTF
Biofrontera AG
14 Jan 20
Current report (foreign)
10:34am